Ultragenyx Pharmaceutical is a biopharmaceutical company focused on identifying, acquiring, developing, and commercializing novel products for treating rare and ultra-rare genetic diseases across Nort... Ultragenyx Pharmaceutical is a biopharmaceutical company focused on identifying, acquiring, developing, and commercializing novel products for treating rare and ultra-rare genetic diseases across North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific region. The company's approved commercial products include Crysvita (burosumab), an antibody for X-linked hypophosphatemia; Mepsevii, an enzyme replacement therapy for mucopolysaccharidosis VII; Dojolvi for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for homozygous familial hypercholesterolemia. Ultragenyx maintains a robust clinical pipeline featuring multiple late-stage candidates in Phase 3 development, including UX111, an AAV9 gene therapy for Sanfilippo syndrome type A; DTX401, an AAV8 gene therapy for glycogen storage disease type Ia; UX143, a monoclonal antibody for osteogenesis imperfecta; and GTX-102, an antisense oligonucleotide for Angelman syndrome. Founded in 2010 and headquartered in Novato, California, the company operates globally to address unmet medical needs in rare genetic disease treatment.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Climate Targets data disclosed by Ultragenyx Pharmaceutical

We reviewed Ultragenyx Pharmaceutical's website and available disclosure materials for the 2023 reporting period and did not identify any reported Climate Targets data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review Ultragenyx Pharmaceutical's data?

Start your 30-day free trial to request a data review for Ultragenyx Pharmaceutical.

Start Free Trial

Legal Center Contact Us

Ultragenyx Pharmaceutical Inc

No Climate Targets data disclosed by Ultragenyx Pharmaceutical

Account Restricted